Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Delivery across the blood-brain barrier: nanomedicine for glioblastoma multiforme.

Jena L, McErlean E, McCarthy H.

Drug Deliv Transl Res. 2019 Nov 14. doi: 10.1007/s13346-019-00679-2. [Epub ahead of print] Review.

PMID:
31728942
2.

Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine.

Kim SS, Harford JB, Pirollo KF, Chang EH.

Biochem Biophys Res Commun. 2015 Dec 18;468(3):485-9. doi: 10.1016/j.bbrc.2015.06.137. Epub 2015 Jun 24. Review.

3.

Harnessing nanomedicine for therapeutic intervention in glioblastoma.

Gutkin A, Cohen ZR, Peer D.

Expert Opin Drug Deliv. 2016 Nov;13(11):1573-1582. Epub 2016 Jun 27. Review.

PMID:
27292970
4.

Novel delivery methods bypassing the blood-brain and blood-tumor barriers.

Hendricks BK, Cohen-Gadol AA, Miller JC.

Neurosurg Focus. 2015 Mar;38(3):E10. doi: 10.3171/2015.1.FOCUS14767. Review.

PMID:
25727219
5.

Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.

van Tellingen O, Yetkin-Arik B, de Gooijer MC, Wesseling P, Wurdinger T, de Vries HE.

Drug Resist Updat. 2015 Mar;19:1-12. doi: 10.1016/j.drup.2015.02.002. Epub 2015 Mar 6. Review.

PMID:
25791797
6.

Targeted Delivery of Functionalized Upconversion Nanoparticles for Externally Triggered Photothermal/Photodynamic Therapies of Brain Glioblastoma.

Tsai YC, Vijayaraghavan P, Chiang WH, Chen HH, Liu TI, Shen MY, Omoto A, Kamimura M, Soga K, Chiu HC.

Theranostics. 2018 Feb 4;8(5):1435-1448. doi: 10.7150/thno.22482. eCollection 2018.

7.

Targeted Vascular Drug Delivery in Cerebral Cancer.

Humle N, Johnsen KB, Arendt GA, Nielsen RP, Moos T, Thomsen LB.

Curr Pharm Des. 2016;22(35):5487-5504. Review.

PMID:
27464719
8.
9.

Nanoparticle technology for drug delivery across the blood-brain barrier.

Lockman PR, Mumper RJ, Khan MA, Allen DD.

Drug Dev Ind Pharm. 2002 Jan;28(1):1-13. Review.

PMID:
11858519
10.

Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials.

Bruinsmann FA, Richter Vaz G, de Cristo Soares Alves A, Aguirre T, Raffin Pohlmann A, Stanisçuaski Guterres S, Sonvico F.

Molecules. 2019 Nov 26;24(23). pii: E4312. doi: 10.3390/molecules24234312. Review.

11.

Nanoparticles: Novel vehicles in treatment of Glioblastoma.

Pourgholi F, Hajivalili M, Farhad JN, Kafil HS, Yousefi M.

Biomed Pharmacother. 2016 Feb;77:98-107. doi: 10.1016/j.biopha.2015.12.014. Epub 2015 Dec 29. Review.

PMID:
26796272
12.

Patented nanomedicines for the treatment of brain tumors.

Caruso G, Raudino G, Caffo M.

Pharm Pat Anal. 2013 Nov;2(6):745-54. doi: 10.4155/ppa.13.56.

PMID:
24237240
13.

Covalent nano delivery systems for selective imaging and treatment of brain tumors.

Ljubimova JY, Sun T, Mashouf L, Ljubimov AV, Israel LL, Ljubimov VA, Falahatian V, Holler E.

Adv Drug Deliv Rev. 2017 Apr;113:177-200. doi: 10.1016/j.addr.2017.06.002. Epub 2017 Jun 10. Review.

14.

Mechanisms of the effectiveness of poly(ε-caprolactone) lipid-core nanocapsules loaded with methotrexate on glioblastoma multiforme treatment.

Pereira NRC, Loiola RA, Rodrigues SF, de Oliveira CP, Büttenbender SL, Guterres SS, Pohlmann AR, Farsky SH.

Int J Nanomedicine. 2018 Aug 15;13:4563-4573. doi: 10.2147/IJN.S168400. eCollection 2018.

15.

Drug delivery approaches for the treatment of glioblastoma multiforme.

Fakhoury M.

Artif Cells Nanomed Biotechnol. 2016 Sep;44(6):1365-73. doi: 10.3109/21691401.2015.1052467. Epub 2015 Jun 5. Review.

PMID:
26046399
16.

Peptide-functionalized and high drug loaded novel nanoparticles as dual-targeting drug delivery system for modulated and controlled release of paclitaxel to brain glioma.

Di Mauro PP, Cascante A, Brugada Vilà P, Gómez-Vallejo V, Llop J, Borrós S.

Int J Pharm. 2018 Dec 20;553(1-2):169-185. doi: 10.1016/j.ijpharm.2018.10.022. Epub 2018 Oct 12.

PMID:
30321641
17.

Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.

Kim SS, Rait A, Kim E, DeMarco J, Pirollo KF, Chang EH.

Cancer Lett. 2015 Dec 1;369(1):250-8. doi: 10.1016/j.canlet.2015.08.022. Epub 2015 Sep 2.

18.

Tumor-Acidity-Cleavable Maleic Acid Amide (TACMAA): A Powerful Tool for Designing Smart Nanoparticles To Overcome Delivery Barriers in Cancer Nanomedicine.

Du JZ, Li HJ, Wang J.

Acc Chem Res. 2018 Nov 20;51(11):2848-2856. doi: 10.1021/acs.accounts.8b00195. Epub 2018 Oct 15. Review.

PMID:
30346728
19.

Breaching barriers in glioblastoma. Part II: Targeted drug delivery and lipid nanoparticles.

Miranda A, Blanco-Prieto MJ, Sousa J, Pais A, Vitorino C.

Int J Pharm. 2017 Oct 5;531(1):389-410. doi: 10.1016/j.ijpharm.2017.07.049. Epub 2017 Aug 9. Review.

PMID:
28801108
20.

Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.

Khaitan D, Reddy PL, Ningaraj N.

Curr Clin Pharmacol. 2018;13(2):110-119. doi: 10.2174/1574884713666180412150153. Review.

PMID:
29651960

Supplemental Content

Support Center